BioSpecifics Technologies (NASDAQ:BSTC) released its quarterly earnings results on Friday. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.14, MarketWatch Earnings reports. BioSpecifics Technologies had a return on equity of 19.59% and a net margin of 49.78%. The company had revenue of $8.17 million during the quarter, compared to analysts’ expectations of $7.19 million.
Shares of NASDAQ:BSTC traded up $0.46 on Friday, hitting $57.96. The company’s stock had a trading volume of 42,537 shares, compared to its average volume of 39,547. BioSpecifics Technologies has a 12 month low of $38.05 and a 12 month high of $66.21. The stock has a market cap of $463.15 million, a price-to-earnings ratio of 34.09 and a beta of 1.48.
Several research firms have recently issued reports on BSTC. BidaskClub raised BioSpecifics Technologies from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 15th. Zacks Investment Research raised BioSpecifics Technologies from a “hold” rating to a “strong-buy” rating and set a $62.00 price target for the company in a research note on Tuesday, August 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $81.00 price target on shares of BioSpecifics Technologies in a research note on Thursday. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. BioSpecifics Technologies has an average rating of “Buy” and a consensus target price of $69.33.
TRADEMARK VIOLATION NOTICE: This report was first posted by BBNS and is owned by of BBNS. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://baseballnewssource.com/2018/11/10/biospecifics-technologies-bstc-releases-quarterly-earnings-results-beats-estimates-by-0-14-eps/2972867.html.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names.
Recommended Story: What is a Reverse Stock Split?
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.